Abstract:PURPOSE Varied therapeutic responses were observed among cancer patients receiving the same treatment regimen, highlighting the challenge of identifying patients most likely to benefit from a given therapy. Here, we present an artificial intelligence-based approach, called CDK4/6 inhibitor Response Model (CRM), to address the complexity of predicting patient responses to treatment by a certain clinical scene on CDK4/6 inhibitors (CDK4/6i).PATIENTS AND METHODS To train the CRM, we transformed the genomic data of 980 breast cancer patients from the TCGA database into activity profiles of signaling pathways (APSP) by utilizing the modified Damage Assessment of Genomic Mutations (DAGM) algorithm. A scoring model was then established by random forest algorithm to classify the HR+/HER2− and HR−/HER2− breast cancer molecular subtypes by the differential APSP features between the two, which reasonably reflected the potential role played by CDK4/6 molecules in HR+/HER2− breast cancer cells. The effectiveness of CRM was then tested in a separate local patient cohort (n = 343) in Guangdong, China. Twin in-silico clinical trials (ICT) of previously disclosed clinical trials ([NCT02246621][1], [NCT02079636][2], [NCT03155997][3], [NCT02513394][4], [NCT02675231][5]) were performed to demonstrate the potential of CRM in generating concerted results as the real-world clinical outcomes.RESULTS The CRM displayed high precision in classifying HR+/HER2− and HR−/HER2− breast cancer patients in both TCGA (AUC=0.9956) and local patient cohorts (AUC=0.9795). Significantly, the scores were distinct (p = 0.025) between CDK4/6i-treated patients with different responses. Breast cancer patients from different subtypes were grouped into five distinct populations based on the scores assigned by the CRM. From twin ICT, the CRM scores reflected the differential responses of patient groups to CDK4/6i-based therapies.CONCLUSION The CRM score showed not only a robust association to clinically observed CDK4/6i responses but also heterogenetic responses across subtypes. More than half of HR+/HER2+ patients may be benefited from CDK4/6i-based treatment. The CRM empowered us to conduct ICT on different types of cancer patients responding to CDK4/6i-based therapies. These findings showed the potential of CRM as the companioned ICT to guide CDK4/6i application in the clinical end. CRM-guided ICT could be a universal method to demonstrate drug sensitivity to various patients.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis work was supported by National Natural Science Foundation of China (grant no. 82072939 to M. Yang), Natural Science Foundation of Guangdong Province (grant no. 2022A1515010425 to M. Yang), Guangzhou Science and Technology Program (grant no. 202206010110 to M. Yang), National Natural Science Foundation of China (grant no. T2125013 to G. Tan), Hefei National Laboratory for Physical Sciences at the Microscale (grant no. KF2020009 to G. Niu).### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Guangdong Provincial People's Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02246621&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02079636&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [3]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03155997&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [4]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02513394&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [5]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02675231&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom

A Clinical Genomics-Guided Prioritizing Strategy Enables Selecting Proper Cancer Cell Lines for Biomedical Research.

Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy

The Genomic Signature of Resistance to Platinum-Containing Neoadjuvant Therapy Based on Single-Cell Data

Optimization of Cell Lines As Tumour Models by Integrating Multi-Omics Data

Precision Therapeutic Biomarker Identification with Application to the Cancer Genome Project

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.

Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery

Conditionally Reprogrammed Colorectal Cancer Cells Combined with Mouse Avatars Identify Synergy Between EGFR and MEK or CDK4/6 Inhibitors

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Development of a prognostic model for NSCLC based on differential genes in tumour stem cells

Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis

Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay.

Patient-derived tumor-like cell clusters for drug testing in cancer therapy

Abstract 5664: Genetic alterations and pharmacological response profiles from 10 cervical cancer cell lines

How clinically relevant are prostate cancer cell lines? A comprehensive characterisation and multiomics comparison

A Genome-Informed Functional Modeling Approach to Evaluate the Responses of Breast Cancer Patients to CDK4/6 Inhibitors-Based Therapies and Simulate Real-World Clinical Trials

Systematic identification of genomic markers of drug sensitivity in cancer cells

High-Throughput Empirical and Virtual Screening to Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer

Precision Anti-Cancer Drug Selection via Neural Ranking